Novel targeted therapies are often directed at signaling molecules, including the PI3Kδ inhibitor idelalisib and the Bruton tyrosine kinase (BTK) inhibitor ibrutinib, both used to treat B cell malignancies, including chronic lymphocytic leukemia (CLL)1. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.